Efficacy and Safety of Neoadjuvant Immunochemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
2507 patients were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Neoadjuvant ICT enhances short-term pathologic and tumor responses in LA-SCCHN versus neoadjuvant chemotherapy, but increases toxicity and lacks proven survival benefits. Further high-quality trials are needed to optimize ICT regimens and identify predictive biomarkers.
[OBJECTIVE] Conventional neoadjuvant chemotherapy yields limited benefits for locally advanced head and neck squamous cell carcinoma (LA-SCCHN) patients.
- p-value P=0.0002
- p-value P=0.007
- 95% CI 2.39-15.43
- OR 6.07
APA
Liu G, Xu C, et al. (2026). Efficacy and Safety of Neoadjuvant Immunochemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.. American journal of clinical oncology. https://doi.org/10.1097/COC.0000000000001304
MLA
Liu G, et al.. "Efficacy and Safety of Neoadjuvant Immunochemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.." American journal of clinical oncology, 2026.
PMID
41671415 ↗
Abstract 한글 요약
[OBJECTIVE] Conventional neoadjuvant chemotherapy yields limited benefits for locally advanced head and neck squamous cell carcinoma (LA-SCCHN) patients. Emerging neoadjuvant immunochemotherapy (ICT) holds potential; however, existing evidence remains conflicting. This study systematically evaluated the efficacy and safety of neoadjuvant ICT in this cohort.
[METHODS] In accordance with PRISMA guidelines, a systematic literature search was performed in PubMed, Web of Science, MEDLINE, and Scopus from inception to July 2025. Cochrane and Joanna Briggs Institute tools were used for bias assessment. The primary endpoints were pathologic complete response (pCR), major pathologic response (mPR), and CR; secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and grade 3 to 4 adverse events.
[RESULTS] Nine studies involving 2507 patients were included. Neoadjuvant ICT significantly improved pCR (6.90% vs. 1.46%; OR=6.07, 95% CI:2.39-15.43; P=0.0002), CR (47.99% vs. 33.14%; OR=2.52, 95% CI:1.29-4.91; P=0.007), and ORR (83.51% vs. 80.04%; OR=2.03, 95% CI:1.17-3.52; P=0.01), with no significant differences in OS, PFS, mPR, or DCR. Grade ≥3 adverse events were more frequent in the neoadjuvant ICT group (56.34% vs. 47.96%; OR=1.32, 95% CI:1.09-1.61; P=0.005).
[CONCLUSION] Neoadjuvant ICT enhances short-term pathologic and tumor responses in LA-SCCHN versus neoadjuvant chemotherapy, but increases toxicity and lacks proven survival benefits. Further high-quality trials are needed to optimize ICT regimens and identify predictive biomarkers.
[METHODS] In accordance with PRISMA guidelines, a systematic literature search was performed in PubMed, Web of Science, MEDLINE, and Scopus from inception to July 2025. Cochrane and Joanna Briggs Institute tools were used for bias assessment. The primary endpoints were pathologic complete response (pCR), major pathologic response (mPR), and CR; secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and grade 3 to 4 adverse events.
[RESULTS] Nine studies involving 2507 patients were included. Neoadjuvant ICT significantly improved pCR (6.90% vs. 1.46%; OR=6.07, 95% CI:2.39-15.43; P=0.0002), CR (47.99% vs. 33.14%; OR=2.52, 95% CI:1.29-4.91; P=0.007), and ORR (83.51% vs. 80.04%; OR=2.03, 95% CI:1.17-3.52; P=0.01), with no significant differences in OS, PFS, mPR, or DCR. Grade ≥3 adverse events were more frequent in the neoadjuvant ICT group (56.34% vs. 47.96%; OR=1.32, 95% CI:1.09-1.61; P=0.005).
[CONCLUSION] Neoadjuvant ICT enhances short-term pathologic and tumor responses in LA-SCCHN versus neoadjuvant chemotherapy, but increases toxicity and lacks proven survival benefits. Further high-quality trials are needed to optimize ICT regimens and identify predictive biomarkers.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- m6A-Modified BASP1 Regulates IL6 Expression to Induce TAM Infiltration to Promote Gastric Cancer Progression.
- Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.
- Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia.
- Effectiveness of the aspiration method in preventing delayed bleeding after gastric endoscopic submucosal dissection.
- Angiotensin‑converting enzyme 2 as an immune and prognostic biomarker in colorectal cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.
- TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response.